JP Morgan to Feature Talk on Vital Vaccine Technology Advancement

HERSHEY, Pa. and ROCKVILLE, Md., January 11, 2015 – Following one of the largest upfront payments for rights to an early-stage allergy vaccine technology, Immunomic Therapeutics, Inc. (ITI) will share the projections for their game-changing DNA vaccine platform with investors at JP Morgan on Wednesday.

The talk will focus on the LAMP-vax platform, a unique vaccine technology that relies on the…

Johns Hopkins University & Immunomic Therapeutics, Inc. Tech Transfer Celebration

On Tues., Nov. 10, Johns Hopkins University and Immunomic Therapeutics, Inc. celebrated the success of the LAMP-vax platform. The technology is a stalwart example of the Johns Hopkins Tech Transfer program, designed to develop new discoveries and inventions into products and services that benefit society.

Tuesday’s event also celebrated Maryland’s ability to nurture new life sciences companies by fostering a community…

ITI Featured in June 20th Edition of BioWorld Insight

In the June 20th edition of BioWorld Insight, editor Marie Powers discusses the allergy market. Her article highlights the growing trend for potential partners (larger pharma and larger biotech) to be seeking new ways to handle allergies as chronic conditions. In the past, allergy was relegated to a secondary position, which did not hold much allure. However, cites Ms. Powers,…

ITI Strives to Help Bring A World Without Food Allergies into Reality

From June 15-18, ITI participated at the Biotechnology Industry Organization (BIO) national conference in Philadelphia, where luminaries from the biotech industry came together to discuss the issues that face it, as well as the potential for biotech breakthroughs that would change the way we practice medicine. We were fortunate enough to have an article written by our CEO, William Hearl,…

Immunomic Therapeutics Provides Insight to High School Students on Antibodies and DNA Vaccines

On June 19, 2015, ITI scientist, Franco Pissani spoke to high school students participating in the Antibody Workshop at Montgomery College in Germantown, MD about immunology, the intricacies of the immune system and how it fights disease, as well as how vaccines work.  He also outlined what is necessary in order to choose a career as a scientist and become…

Immunomic Therapeutics Featured In Genetic Engineering and Biotechnology News

We are happy to report that the June 1, 2015 issue of Genetic Engineering and Biotechnology News featured an article on ITI called, “Not Your ‘Old School’ Immune System.”  The article, written by reporter Gail Dutton, is a result of an interview with our CEO, Bill Hearl, where he explained how utilizing LAMP protein provides a two-tiered approach toward using…

Highlights from Immunomic Therapeutics, Inc. Annual Shareholders Meeting

On May 28th, Immunomics Therapeutics, Inc. (ITI) conducted its annual shareholders meeting.
During the meeting, we discussed our goals for the future, while reflecting on the year gone by.  It’s been a good year for ITI, and the future seems even brighter.  Highlights from the presentation include:
1. The completion of our first major licensing agreement with Astellas Pharma to produce our…

Contributing to the Growth of Vaccine and Immunotherapeutics Development in Maryland

Earlier this month, we had the pleasure to attend the first ever Atlantic Vaccines and Immunotherapeutics Summit, hosted by the Tech Council of Maryland’s MD Bio.  The event gathered together local business leaders, scientists, government officials, and other notable members of the biosciences ecosystem, within the state and outside of it, to discuss the increasing role the state of Maryland…

Embarking on a Solution to Food Allergies

 

Many of you may have noticed that we announced a $1.2 million grant by the Department of Defense (DoD) that will be employed for the application of our LAMP-vax platform to peanut allergies.  Food allergies affect about 15 million Americans each year, and have a healthcare cost of about $25billion, due to a variety of factors such as emergency room visits, other…